Jan Eckmann
Research Subjects
Jan Eckmann has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Cornelia Handl
Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland
12 shared publications - Elena Élez
Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
12 shared publications - Florian Renner
Maria Vieito, MD, Vall d’Hebron University Hospital, Universidad Autonoma de Barcelona, Barcelona, Spain, Elisa Fontana, MD, PhD, Sarah Cannon Research Institute, London, United Kingdom, Gabriel Schnetzler, MD, David Dejardin, PhD, Florian Renner, PhD, and Andreas Roller, PhD, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland, Nino Keshelava, MD, Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
12 shared publications - Gabriel Schnetzler
Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
12 shared publications - Hector G. Palmer
Vall d’Hebrón Institut d’Oncología (VHIO), Stem Cell and Cancer Laboratory, Barcelona, Spain
12 shared publications - Irene Chicote
Stem Cells and Cancer Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
12 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig S8 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Kaplan Meier survival curves for PDX models shown in figure 5
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig S8 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Kaplan Meier survival curves for PDX models shown in figure 5
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
The therapeutic benefit of the combination of the first-generation BRAF inhibitor (BRAFi) encorafenib and the EGFR-blocking antibody cetuximab in second-line metastatic colorectal cancers harboring BRAFV600E mutations remains limited and short lived. In this study, we present the preclinical characterization of the next-generation BRAFi mosperafenib (RG6344/RO7276389) in colorectal cancer models. Mosperafenib was designed as an MAPK paradox breaker. As it does not trigger phosphorylated ERK overactivation in BRAF wild-type contexts, we hypothesized that it may lead to an improved safety profile while reaching higher target coverage in the clinic. In in vivo experiments conducted in BRAFi-naïve xenograft models, mosperafenib monotherapy outperformed encorafenib/cetuximab at clinically relevant doses, indicating higher activity of mosperafenib. The combination of mosperafenib and cetuximab demonstrated potent activity with tumor regression and long survival benefits in BRAFi-naïve models and in patient-derived xenograft models derived from patients who progressed to encorafenib/cetuximab therapy, supporting the activity of mosperafenib even in BRAFi-experienced patients. Additional combination studies of mosperafenib with FOLFOX resulted in tumor regression and superior activity compared with the same combination with encorafenib. Collectively, these data provide a strong preclinical rationale for the potentially transformative activity of mosperafenib as monotherapy and as a preferred backbone BRAFi for combinatorial regimen for BRAF-mutated colorectal cancer.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
The therapeutic benefit of the combination of the first-generation BRAF inhibitor (BRAFi) encorafenib and the EGFR-blocking antibody cetuximab in second-line metastatic colorectal cancers harboring BRAFV600E mutations remains limited and short lived. In this study, we present the preclinical characterization of the next-generation BRAFi mosperafenib (RG6344/RO7276389) in colorectal cancer models. Mosperafenib was designed as an MAPK paradox breaker. As it does not trigger phosphorylated ERK overactivation in BRAF wild-type contexts, we hypothesized that it may lead to an improved safety profile while reaching higher target coverage in the clinic. In in vivo experiments conducted in BRAFi-naïve xenograft models, mosperafenib monotherapy outperformed encorafenib/cetuximab at clinically relevant doses, indicating higher activity of mosperafenib. The combination of mosperafenib and cetuximab demonstrated potent activity with tumor regression and long survival benefits in BRAFi-naïve models and in patient-derived xenograft models derived from patients who progressed to encorafenib/cetuximab therapy, supporting the activity of mosperafenib even in BRAFi-experienced patients. Additional combination studies of mosperafenib with FOLFOX resulted in tumor regression and superior activity compared with the same combination with encorafenib. Collectively, these data provide a strong preclinical rationale for the potentially transformative activity of mosperafenib as monotherapy and as a preferred backbone BRAFi for combinatorial regimen for BRAF-mutated colorectal cancer.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig S2 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Quantification of immunoblotting of figure 3A,B,C
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig S2 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Quantification of immunoblotting of figure 3A,B,C
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Figure S5 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Shows body weight of mice reported in fig 5
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure S5 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Shows body weight of mice reported in fig 5
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig S3 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Western blot showing additive effect of combined inhibition of EGFR and MAPK signaling
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig S3 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Western blot showing additive effect of combined inhibition of EGFR and MAPK signaling
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig S6 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
In vivo efficacy of BRAFi in combination with bevacizumab in LS411N
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig S6 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
In vivo efficacy of BRAFi in combination with bevacizumab in LS411N
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig S4 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Tumor volumes of Figure 4 on a logarithmic scale
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig S4 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Tumor volumes of Figure 4 on a logarithmic scale
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig S9 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
In vitro combination of mosperafenib, binimetinib, and FOLFOX in RKO cells
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig S9 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
In vitro combination of mosperafenib, binimetinib, and FOLFOX in RKO cells
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Suppl Table 1 shows the genetic background of PDX models
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Suppl Table 1 shows the genetic background of PDX models
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Suppl Figure S7 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Clinicopathological data from PDX models shown in figure 5
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure S7 from Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Clinicopathological data from PDX models shown in figure 5